-
公开(公告)号:ES2187501T3
公开(公告)日:2003-06-16
申请号:ES93103301
申请日:1993-03-02
Applicant: HOECHST AG
Inventor: HEITSCH HOLGER DR , HENNING RAINER DR , WAGNER ADALBERT DR , GERHARDS HERMANN DR , BECKER REINHARD DR , SCHOLKENS BERNWARD PROF DR
IPC: A61K31/4164 , A61K31/64 , A61P9/10 , A61P9/12 , A61K31/415 , C07D233/84 , C07D233/86 , C07D233/90
Abstract: Compounds of the formula (I) in which R is, for example, ethyl, R is, for example, methyl, n is, for example, zero, R is, for example, COOH and R is, for example, SO2NHCONHCH3 are highly active antagonists of angiotensin II receptors.
-
公开(公告)号:CZ286187B6
公开(公告)日:2000-02-16
申请号:CZ283097
申请日:1997-09-08
Applicant: HOECHST AG
Inventor: BECKER REINHARD DR , HENNING RAINER DR , TEETZ VOLKER DR , URBACH HANSJOERG DR
IPC: A61K38/55 , A61K31/275 , A61K31/277 , A61K31/40 , A61K31/401 , A61K31/41 , A61K31/425 , A61K31/455 , A61K31/47 , A61K31/55 , A61K45/06 , A61P3/00 , A61P3/14 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00
Abstract: In the present invention there is disclosed a pharmaceutical preparation intended for treating proteinuria and containing as an active substance a combination of trandolapril and verapamil.
-
公开(公告)号:ES2114874T3
公开(公告)日:1998-06-16
申请号:ES91122406
申请日:1992-01-01
Applicant: HOECHST AG
Inventor: WAGNER ADALBERT DR , ENGLERT HEINRICH DR , KLEEMANN HEINZ-WERNER DR , GERHARDS HERMANN DR , SCHOLKENS BERNWARD PROF DR , BECKER REINHARD DR
IPC: A61K31/40 , A61K31/415 , A61K31/425 , A61K31/435 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/505 , A61K31/535 , A61K31/54 , A61K31/64 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , C07D207/34 , C07D207/36 , C07D233/54 , C07D233/66 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D249/02 , C07D255/02 , C07D257/02 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D453/02 , C07D521/00
Abstract: Azole derivative of the general formula (I) in which A, L, O, R , X, Y, Z and q have the meanings given, a process for their preparation, pharmaceutical preparations and the use of the compounds are described. Azole derivatives of the formula I where the symbols have, for example, the following meanings: R = (C2-C10)-alkyl Z = nitrogen X and Y = independently of one another CR L = -CH2- q = zero or 1 A = biphenyl radical which is substituted, for example, by R R = halogen or hydrogen R = SO2-NH-CO-OR and R = phenyl, are highly active antagonists of angiotensin II receptors.
-
公开(公告)号:PH30954A
公开(公告)日:1997-12-23
申请号:PH43726
申请日:1992-01-02
Applicant: HOECHST AG
Inventor: WAGNER ADALBERT DR , ENGLERT HEINRICH DR , KLEEMANN HEINZ-WERNER DR , GERHARDS HERMANN DR , SCHOLKENS BERNWARD PROF DR , BECKER REINHARD DR , LINZ WOLFGANG DR , JEAN-PAUL VEVERT , JOHN-CLAUDE CAILLE
IPC: A61K31/415 , A61K31/425 , A61K31/435 , A61K31/44 , A61K31/4427 , A61K31/40 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/505 , A61K31/535 , A61K31/54 , A61K31/64 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , C07D207/34 , C07D207/36 , C07D233/54 , C07D233/66 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D249/02 , C07D255/02 , C07D257/02 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D453/02 , C07D521/00 , A61K31/41
Abstract: Azole derivative of the general formula (I) in which A, L, O, R , X, Y, Z and q have the meanings given, a process for their preparation, pharmaceutical preparations and the use of the compounds are described. Azole derivatives of the formula I where the symbols have, for example, the following meanings: R = (C2-C10)-alkyl Z = nitrogen X and Y = independently of one another CR L = -CH2- q = zero or 1 A = biphenyl radical which is substituted, for example, by R R = halogen or hydrogen R = SO2-NH-CO-OR and R = phenyl, are highly active antagonists of angiotensin II receptors.
-
公开(公告)号:DE58906338D1
公开(公告)日:1994-01-20
申请号:DE58906338
申请日:1989-05-23
Applicant: HOECHST AG
Inventor: BECKER REINHARD DR , HENNING RAINER DR , URBACH HANSJOERG DR , TEETZ VOLKER DR , ENGLERT HEINRICH CHRISTIAN DR , MANIA DIETER DR
Abstract: The invention relates to combinations of angiotensin converting enzyme inhibitors with potassium channel modulators, process for the preparation thereof and their use as medicines.
-
公开(公告)号:CS9200010A3
公开(公告)日:1992-07-15
申请号:CS1092
申请日:1992-01-03
Applicant: HOECHST AG
Inventor: WAGNER ADALBERT DR , ENGLERT HEINRICH DR , KLEEMANN HEINZ-WERNER DR , GERHARDS HERMANN DR , SCHOLKENS BERNWARD PROF DR , BECKER REINHARD DR , LINZ WOLFGANG DR
IPC: A61K31/40 , A61K31/415 , A61K31/425 , A61K31/435 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/505 , A61K31/535 , A61K31/54 , A61K31/64 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , C07D207/34 , C07D207/36 , C07D233/54 , C07D233/66 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D249/02 , C07D255/02 , C07D257/02 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D453/02 , C07D521/00 , A61K31/41 , C07D207/30 , C07D231/10 , C07D249/04 , C07D249/08
CPC classification number: C07D231/12 , C07D233/56 , C07D233/68 , C07D233/70 , C07D233/90 , C07D249/08 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D453/02
-
公开(公告)号:CS9103587A3
公开(公告)日:1992-06-17
申请号:CS358791
申请日:1991-11-26
Applicant: HOECHST AG
Inventor: BECKER REINHARD DR , HENNING RAINER DR , TEETZ VOLKER DR , URBACH HANSJORG DR
IPC: A61K38/55 , A61K31/275 , A61K31/277 , A61K31/40 , A61K31/401 , A61K31/41 , A61K31/425 , A61K31/455 , A61K31/47 , A61K31/55 , A61K45/06 , A61P3/00 , A61P3/14 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , A61K37/64 , A61K31/44
CPC classification number: A61K38/556 , A61K31/44 , A61K31/55 , A61K31/275 , A61K2300/00
-
公开(公告)号:CS358791A3
公开(公告)日:1992-06-17
申请号:CS358791
申请日:1991-11-26
Applicant: HOECHST AG
Inventor: BECKER REINHARD DR , HENNING RAINER DR , TEETZ VOLKER DR , URBACH HANSJORG DR
IPC: A61K38/55 , A61K31/275 , A61K31/277 , A61K31/40 , A61K31/401 , A61K31/41 , A61K31/425 , A61K31/455 , A61K31/47 , A61K31/55 , A61K45/06 , A61P3/00 , A61P3/14 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , A61K37/64 , A61K31/44
Abstract: An angiotensin converting enzyme inhibitor (I) can be used in combination with Ca antagonists (III) in the prevention and therapy of proteinuria. Pref. (A) Ramipril and felodipine; (B) Ramipril and 4-(2,3-dichlorophenyl) -2,6-dimethyl-3- (1,2,4-oxadiazol-5-yl) -S-isopropoxy carbonyl-1,4-dihydropyridine (IIb), (c) Trandolapril and felodipine; (D) Trandolapril and (IIb), (E) Trandolapril and Verapamil; (F) Quinapril and felodipine; (G) Quinapril and (IIIb) or the physiologically acceptable salts of these components.
-
公开(公告)号:CS409591A3
公开(公告)日:1992-04-15
申请号:CS409591
申请日:1991-12-27
Applicant: HOECHST AG
Inventor: URBACH HANSJORG DR , HENNING RAINER DR , TEETZ VOLKER DR , GEIGER ROLF PROF DR , BECKER REINHARD DR , GAUL HOLGER
IPC: A61K38/55 , A61K31/40 , A61K31/403 , A61K31/404 , A61K38/00 , A61P7/10 , A61P9/08 , A61P9/12 , C07D209/02 , C07D209/08 , C07D209/32 , C07D209/34 , C07D209/42 , C07D209/52 , C07D215/22 , C07D215/227 , C07K1/02 , C07K1/113 , C07K5/02 , C07K5/06
Abstract: 1. Claims for the Contracting states ; BE, CH, DE, FR, GB, IT, Li, Lu, NL, SE A compound of the formula I see diagramm : EP0084164,P21,F7 in which the hydrogen atoms on the bridgehead C atoms 3a and (6+n)a have the trans configuration relative to one another and wherein n denotes 0, 1 or 2, R1 denotes methyl, R2 denotes hydrogen, (C1 -C4 )-alkyl or benzyl, Y denotes hydrogen or hydroxyl, Z denotes hydrogen or Y and Z together denote oxygen and X denotes phenyl, and its physiologically acceptable salts. 1. Claims for the Contracting state : Austria A process for the preparation of the compounds of the formula I see diagramm : EP0084164,P24,F4 in which the hydrogen atoms on the bridgehead C atoms 3a and (6+n)a have the trans configuration relative to one another and wherein n denotes 0, 1 or 2, R1 denotes methyl, R2 denotes hydrogen, (C1 -C4 )-alkyl or benzyl, Y denotes hydrogen or hydroxyl, Z denotes hydrogen or Y and Z together denote oxygen and X denotes phenyl, and its physiologically acceptable salts, which a) comprises reacting a compound of the formula II see diagramm : EP0084164,P24,F6 wherein R1 , R2 , X, Y and Z have the meanings as in formula I, with a compound of the formula III see diagramm : EP0084164,P25,F1 in which the H atoms on the C atoms 3a and (6+n)a have the trans configuration relative to one another and wherein n denotes 0, 1 or 2 and W denotes a radical which can be cleaved off by hydrogenolysis or by acid, and subsequently splitting off the radical W and, if appropriate, the radical R2 to form the free carboxyl groups, or b) for the preparation of compounds of the formula I, in which Y and Z together denote oxygen, comprises b1 ) reacting a compound of the formula IV see diagramm : EP0084164,P25,F3 in which the H atoms on the C atoms 3a and (6+n)a have the trans configuration relative to one another and wherein n and R1 have the meanings as in formula I and W has the meaning as in formula III, with a compound of the formula V, R2 O2 C-CH = CH-CO-X wherein R2 and X have the meanings as in formula I, and subsequently splitting off the radical W and, if appropriate, also the radical R2 to form the free carboxyl groups, or, b2 ) reacting a compound of the formula IV mentioned under b1 ) with a compound of the general formula VI, wherein R2 has the meaning as in formula I, and with a compound of the general formula VII OHC-CO2 R2 X-CO-CH3 wherein X has the meaning as in formula I, subsequently splitting off the radical W and, if appropriate, the radical R2 to form the free carboxyl group, or c) for the preparation of compounds of the formula I, in which Y and Z each denote hydrogen, comprises c1 ) reacting a compound of the formula IV mentioned under b1 ) with a compound of the formula VIII see diagramm : EP0084164,P25,F2 wherein R2 and X have the meanings as in formula I, reducing the Schiff's bases obtained and subsequently splitting off the radical W and, if appropriate, the radical R2 to form the free carboxyl groups, or c2 ) catalytically reducing a compound of the formula I in which Y and Z together denote oxygen, with hydrogen, or d) for the preparation of compounds of the formula I, in which Y denotes hydroxyl and Z denotes hydrogen, comprises reducing a compound of the formula I, in which Y and Z together denote oxygen, catalytically with hydrogen or with a reducing agent, such as sodium borohydride, and, if appropriate, converting the compounds obtained according to (a)-(d) into their physiologically acceptable salts.
-
公开(公告)号:DE3280014D1
公开(公告)日:1989-12-14
申请号:DE3280014
申请日:1982-12-24
Applicant: HOECHST AG
Inventor: URBACH HANSJORG DR , HENNING RAINER DR , TEETZ VOLKER DR , GEIGER ROLF PROF DR , BECKER REINHARD DR , GAUL HOLGER
IPC: A61K38/55 , A61K31/40 , A61K31/403 , A61K31/404 , A61K38/00 , A61P7/10 , A61P9/08 , A61P9/12 , C07D209/02 , C07D209/08 , C07D209/32 , C07D209/34 , C07D209/42 , C07D209/52 , C07D215/22 , C07D215/227 , C07K1/02 , C07K1/113 , C07K5/02 , C07K5/06
Abstract: 1. Claims for the Contracting states ; BE, CH, DE, FR, GB, IT, Li, Lu, NL, SE A compound of the formula I see diagramm : EP0084164,P21,F7 in which the hydrogen atoms on the bridgehead C atoms 3a and (6+n)a have the trans configuration relative to one another and wherein n denotes 0, 1 or 2, R1 denotes methyl, R2 denotes hydrogen, (C1 -C4 )-alkyl or benzyl, Y denotes hydrogen or hydroxyl, Z denotes hydrogen or Y and Z together denote oxygen and X denotes phenyl, and its physiologically acceptable salts. 1. Claims for the Contracting state : Austria A process for the preparation of the compounds of the formula I see diagramm : EP0084164,P24,F4 in which the hydrogen atoms on the bridgehead C atoms 3a and (6+n)a have the trans configuration relative to one another and wherein n denotes 0, 1 or 2, R1 denotes methyl, R2 denotes hydrogen, (C1 -C4 )-alkyl or benzyl, Y denotes hydrogen or hydroxyl, Z denotes hydrogen or Y and Z together denote oxygen and X denotes phenyl, and its physiologically acceptable salts, which a) comprises reacting a compound of the formula II see diagramm : EP0084164,P24,F6 wherein R1 , R2 , X, Y and Z have the meanings as in formula I, with a compound of the formula III see diagramm : EP0084164,P25,F1 in which the H atoms on the C atoms 3a and (6+n)a have the trans configuration relative to one another and wherein n denotes 0, 1 or 2 and W denotes a radical which can be cleaved off by hydrogenolysis or by acid, and subsequently splitting off the radical W and, if appropriate, the radical R2 to form the free carboxyl groups, or b) for the preparation of compounds of the formula I, in which Y and Z together denote oxygen, comprises b1 ) reacting a compound of the formula IV see diagramm : EP0084164,P25,F3 in which the H atoms on the C atoms 3a and (6+n)a have the trans configuration relative to one another and wherein n and R1 have the meanings as in formula I and W has the meaning as in formula III, with a compound of the formula V, R2 O2 C-CH = CH-CO-X wherein R2 and X have the meanings as in formula I, and subsequently splitting off the radical W and, if appropriate, also the radical R2 to form the free carboxyl groups, or, b2 ) reacting a compound of the formula IV mentioned under b1 ) with a compound of the general formula VI, wherein R2 has the meaning as in formula I, and with a compound of the general formula VII OHC-CO2 R2 X-CO-CH3 wherein X has the meaning as in formula I, subsequently splitting off the radical W and, if appropriate, the radical R2 to form the free carboxyl group, or c) for the preparation of compounds of the formula I, in which Y and Z each denote hydrogen, comprises c1 ) reacting a compound of the formula IV mentioned under b1 ) with a compound of the formula VIII see diagramm : EP0084164,P25,F2 wherein R2 and X have the meanings as in formula I, reducing the Schiff's bases obtained and subsequently splitting off the radical W and, if appropriate, the radical R2 to form the free carboxyl groups, or c2 ) catalytically reducing a compound of the formula I in which Y and Z together denote oxygen, with hydrogen, or d) for the preparation of compounds of the formula I, in which Y denotes hydroxyl and Z denotes hydrogen, comprises reducing a compound of the formula I, in which Y and Z together denote oxygen, catalytically with hydrogen or with a reducing agent, such as sodium borohydride, and, if appropriate, converting the compounds obtained according to (a)-(d) into their physiologically acceptable salts.
-
-
-
-
-
-
-
-
-